Clinical characteristics of treatment-resistant depression in adults in Hungary: Real-world evidence from a 7-year-long retrospective data analysis

PLoS One. 2021 Jan 20;16(1):e0245510. doi: 10.1371/journal.pone.0245510. eCollection 2021.

Abstract

Purpose: Treatment-resistant depression (TRD) is associated with a poor quality of life and high economic burden. This observational retrospective epidemiological study aimed to estimate the proportion of patients with TRD within a cohort of patients with major depressive disorder (MDD) in Hungary and examine the mortality and comorbidities of patients with and without TRD.

Patients and methods: This study included patients with MDD who experienced onset of a new depressive episode between 01 January 2009 and 31 August 2015, using data from a nationwide, longitudinal database.

Results: Overall, 99,531 patients were included in the MDD cohort, of which 8,268 (8.3%) also met the criteria for TRD. The overall survival of non-TRD patients was longer than in TRD patients; the risk of mortality for TRD patients was significantly higher than of non-TRD patients (HR [CI] 1.381 [1.212-1.571]; p<0.001). Patients with TRD had a significantly higher probability of having "Neurotic, stress-related and somatoform disordersˮ, autoimmune conditions, cardio- or cerebrovascular diseases, thyroid gland diseases and self-harming behaviour not resulting in death than non-TRD patients (for all comparisons, p values were less than 0.005).

Discussion: To our best knowledge, this is the first study to assess the frequency of TRD in Hungary. In a cohort of Hungarian MDD patients, we have found that the proportion of TRD (~8.3%) is comparable to those reported in previous studies with similar methodology from other countries. The majority of our other main findings (e.g. more frequent self-harming behaviour, increased risk of "Neurotic, stress-related and somatoform disordersˮ and higher overall mortality in TRD subjects) are also in line with previous results from other countries. Taking the substantial proportion of patients with TRD into consideration, a more comprehensive and targeted treatment strategy would be required for these individuals.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Cohort Studies
  • Depression / therapy*
  • Female
  • Humans
  • Hungary
  • Male
  • Middle Aged
  • Retrospective Studies
  • Treatment Failure*
  • Young Adult

Grants and funding

The study was funded by Janssen: Pharmaceutical Companies of Johnson & Johnson (www.janssen.com). PK, LF, SMH, SB are employees of Janssen, PT was an employee of Janssen during the time the study was carried out. Janssen provided funds for Healthware Ltd. for their participation in the study. TB, KD are employees of Healthware Ltd. Editorial assistance in the development of this manuscript was provided by Open Health Medical Communications (UK), with financial support from Janssen. The authors retained full editorial control over the content of the manuscript and the decision to publish it. The funder provided support in the form of salaries for authors PK, LF, SMH, SB, PT, provided funds for the data access, provided funds to Healthware Ltd., and provided funds for medical writing. The funder did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.